BioIntelliSense Collects Patient Data with New BioHub

Biometrics News - BioIntelliSense Collects Patient Data with New BioHub

BioIntelliSense is continuing to build its Data-as-a-Service portfolio with the release of a new 5G BioHub. The BioHub arrives shortly after BioIntelliSense received FDA clearance for its new on-body medical sensor, which has been dubbed the BioSticker.

The BioHub was specifically designed to deployed alongside the BioSticker, though it is compatible with other third party medical devices. The Hub will essentially act as a connectivity gateway that syncs up with the health tracking devices being used to monitor a patient. The gateway will consolidate the data generated by those devices, and automatically upload it to the BioIntelliSense Cloud for future analysis and record keeping purposes.

The BioHub is built with a Qualcomm 5G chip set and comes with an embedded data plan. BioIntelliSense has partnered with the KORE Wireless Group to ensure strong connectivity with more than 24 carriers around the world. That includes the AT&T network, which has already certified the BioHub ahead of its U.S. launch.

“All of us at KORE are excited to support the pioneering work being done at BioIntelliSense,” said KORE President and CEO Romil Bahl. “Remote Patient Monitoring and related use cases represent a terrific opportunity to improve the efficacy and efficiency of healthcare delivery.”

According to BioIntelliSense, the BioHub will make it much easier to monitor patients remotely in clinical settings and in the home. The near real-time data transferred through the BioHub is encrypted, while the device itself can be used for both primary care and large-scale clinical trials. 

BioIntelliSense is not the only company working to improve healthcare data practices. For example, Nuance recently released a new Ambient Clinical Intelligence that securely records doctor-patient interactions in real time. The solution is expected to reduce the administrative burden and decrease burnout for medical professionals, thereby addressing one of the more serious problems currently facing the medical industry.